Liposcience, Inc.

Other

Lipscience, Inc.

Dennis W Bennett

James D Otvos

Justyna E Wolak-Dinsmore

Thomas M O'Connell

Irina Y Shalaurova

Elias J Jeyarajah

Kelly Mercier

Stanley Leon Hazen

Steven P Matyus

Stanley L Hazan

John Contois

Lili Duan

Qun Zhou

Steve Markham

Russell Reeve

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide ('TMAO'). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 &#x3bc;M or urine with a normal biologic range of between about 0-1000 &#x3bc;M.

NMR quantification of TMAO

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Multi-parameter diabetes risk evaluations

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of 'GlycA' in arbitrary units or in defined units (e.g., &#x3bc;mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

NMR measurements of NMR biomarker GlycA

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Methods, computer program products, NMR assays and automated/semi-automated systems measure concentrations of ionized calcium and/or magnesium or other metabolites in clinical biosamples using NMR data obtained from an NMR spectrometer, such as a clinical NMR Analyzer.

NMR measurement of clinically relevant ionized biosample constituents such as ionized calcium and/or magnesium

Methods, systems and computer programs are configured to determine the presence of and/or a measurement for a plurality of constituents in a composite signal with closely correlated chemical constituents having overlapping signal lineshapes extending about a spectrum of interest obtained from a target sample undergoing analysis.

Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals

Methods for assessing the risk of developing Type 2 diabetes and other related disorders include obtaining an NMR derived reference spectrum for a known glucose concentration sample and storing this information as a reference standard. A patient blood sample is collected and NMR derived patient spectrums for the blood sample are obtained. The two NMR data sets (the reference and the patient) are compared and a glucose concentration is determined for the patient sample. The glucose concentration can be evaluated with a blood sample undergoing lipoprotein cholesterol evaluation. The NMR based test can be used to concurrently provide a glucose concentration and lipoprotein constituent values based on a single testing event. The disclosure also includes a multi-purpose test, i.e., a test which concurrently provides lipoprotein screening and coronary heart disease risk evaluation along with a diabetes screening and risk assessment for developing Type 2 diabetes. A method for assessing diabetes includes identifying the presence of diabetic dyslipidemia based on the values of predetermined NMR measured lipoprotein constituents.

Growing community of inventors

Shorewood, WI, United States of America

Dennis W Bennett